Related Experiment Video
Updated: May 21, 2026

Comprehensive Analysis of Procoagulant Platelets Exhibiting Features of Necrosis, Apoptosis and Platelet Activation
Published on: May 23, 2025
Higher coated-platelet levels are associated with chronic hypertension in patients with transient ischemic attack
Calin I Prodan1, Andrea S Vincent, George L Dale
1Neurology Service, Department of Neurology, Veterans Administration Medical Center, University of Oklahoma Health Sciences Center , Oklahoma City, OK 73104, USA. calin-prodan@ouhsc.edu
Insights
Coated-platelet levels, elevated in TIA patients, correlate with hypertension and longer symptom duration. This suggests a link between hypertension and increased platelet thrombotic potential in TIA.
Area of Science:
- Hematology
- Neurology
- Cardiovascular Medicine
Background:
- Coated-platelets are procoagulant platelets linked to transient ischemic attack (TIA) risk.
- Previous studies show elevated coated-platelet levels in TIA patients correlating with ABCD2 scores.
Purpose of the Study:
- To investigate the impact of individual ABCD2 score components on coated-platelet levels in TIA patients.
- To explore the relationship between hypertension, symptom duration, and platelet procoagulant activity.
Main Methods:
- Coated-platelet levels were measured in 124 TIA patients.
- A nine-way ANOVA analyzed the influence of ABCD2 score elements, including blood pressure (BP) and hypertension (HTN), on coated-platelet levels.
Main Results:
- Elevated BP (≥140/90) was initially associated with higher coated-platelet levels.
- Hypertension (HTN) showed a significant main effect, with higher levels in HTN patients (46.3% vs. 33.6%, p<0.0001).
- Longer symptom duration (≥60 minutes) also correlated with increased coated-platelet levels (42.5% vs. 37.4%, p=0.031).
Conclusions:
- Hypertension is a significant factor associated with elevated coated-platelet levels in TIA patients.
- Findings suggest a link between chronic hypertension and heightened platelet thrombotic potential.
- Symptom duration may also influence platelet activation in TIA.
Abstract:
Coated-platelets are procoagulant platelets observed upon dual stimulation with collagen and thrombin. We previously reported that coated-platelet levels are elevated in patients with transient ischemic attack (TIA) compared to controls and that these levels correlate with ABCD2 scores, a validated tool for identifying the short-term risk for stroke occurrence in TIA patients. We now investigate the effect of individual elements of the ABCD2 score on coated-platelet levels in TIA. Coated-platelet levels were measured in 124 TIA patients. A nine-way ANOVA evaluated the impact of components of the ABCD2 score (age, blood pressure (BP), clinical features, symptom duration, and diabetes), smoking, pertinent medications, race, and gender on coated-platelet levels. In the initial model, the only significant main effect was for BP; patients with BP ≥ 140/90 had higher coated-platelet levels than those without (mean ± SEM; 44.0 ± 2.1% vs. 35.4 ± 2.3%, p = 0.0007). Because the diagnosis of hypertension (HTN) requires multiple readings of elevated BP, we re-analyzed the data by replacing BP with HTN. In the second model, there were two significant main effects: HTN - with higher coated-platelet levels in patients with vs. those without HTN (46.3 ± 2.1% vs. 33.6 ± 2.1%, p < 0.0001), and symptom duration - with higher coated-platelet levels in patients with duration ≥60 minutes vs. those with duration <60 minutes (42.5 ± 2.0% vs. 37.4 ± 2.1%, p = 0.031). These data suggest a link between chronic HTN and platelet thrombotic potential.
Related Concept Videos
Transient Ischemic Attack l: Introduction
Hypertension III: Clinical Manifestations and Diagnostic Studies
Formation of the Platelet Plug
As the injured blood vessel contracts, endothelial cells undergo contraction, revealing collagen fibers in the basement membrane and underlying connective tissue. Furthermore, the plasma membrane of endothelial cells becomes adhesive, preparing the site for platelet adhesion. Platelets...
Antiplatelet Drugs: Prostaglandin Synthesis, P2Y12 and Glycoprotein IIb/IIIa Inhibitors
Prostaglandin synthesis inhibitors, exemplified by the widely known aspirin, wield their power by irreversibly acetylating...
Hypertension II: Pathophysiology
Anticoagulant Drugs: Low-Molecular-Weight Heparins

